CBOE Cboe Global Markets Forecast, Technical & Fundamental Analysis

CBOE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CBOE turned positive on January 14, 2025. Looking at past instances where CBOE's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 21, 2025. You may want to consider a long position or call options on CBOE as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CBOE moved above its 50-day moving average on January 27, 2025 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for CBOE moved out of overbought territory on January 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBOE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CBOE broke above its upper Bollinger Band on January 27, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CBOE entered a downward trend on January 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 67, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.869) is normal, around the industry mean (5.562). P/E Ratio (25.769) is within average values for comparable stocks, (34.442). CBOE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.610). Dividend Yield (0.012) settles around the average of (0.030) among similar stocks. P/S Ratio (5.171) is also within normal values, averaging (113.078).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CBOE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.